[1]ACSMedicinalChemistryLetters,2012,vol.3,#10,p.850-855
[2]BioorganicandMedicinalChemistryLetters,2018,vol.28,#4,p.694-699
[1]ACSMedicinalChemistryLetters,2012,vol.3,#10,p.850-855
[1]ACSMedicinalChemistryLetters,2012,vol.3,#10,p.850-855
[1]ACSMedicinalChemistryLetters,2012,vol.3,#10,p.850-855
[1]ACSMedicinalChemistryLetters,2012,vol.3,p.850-855
[2]BioorganicandMedicinalChemistryLetters,2018,vol.28,p.694-699
[1]ACSMedicinalChemistryLetters,2012,vol.3,p.850-855
[1]ACSMedicinalChemistryLetters,2012,vol.3,p.850-855
[1]ACSMedicinalChemistryLetters,2012,vol.3,p.850-855
Title: Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Journal: Oncotarget 20150520
Title: Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule.
Journal: The Journal of biological chemistry 20150109
Title: An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Journal: Science (New York, N.Y.) 20130503
Title: Rohle D, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013 May 3;340(6132):626-30.
Title: Molenaar RJ, et al. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Res. 2015 Nov 15;75(22):4790-802.